Former Merck Serono CEO proposed as chairman of Calliditas Therapeutics

The nominations committee of Swedish firm Calliditas Therapeutics (Nasdaq Stockholm: CALTX) has proposed that Elmar Schnee becomes a board member and chairman of the company.

Mr Schnee was previously chief executive of Merck Serono and was instrumental in the acquisition of Serono by Merck KGaA. He has also served as general partner and member of the executive board of Merck KGaA and has held previously several senior global management positions with UCB and Sanofi.

The committee also proposed the appointment of Diane Parks as a board member. Ms Parks is a senior executive with deep sales and marketing experience from the USA, where she has held positions such as head of US commercial for Kite Pharma, vice president of sales for Amgen and head of global marketing at Pharmacyclics.